CXCR3 and neoplasm: Importantly, blocking the CXCR9-CXCR3 axis abolished both the overall tumor growth-suppressing effects (Figure 6A) and the overall immune-responsive transcriptomic changes in the tumors treated with CXCR3-neutralizing antibodies (Figure 7D) induced by DB, suggesting that the CXCR9-CXCR3 chemokine axis is a main driver of anti-tumor immune responses triggered by DB.